Orbimed Capital LLC insider trades: ARS Pharmaceuticals (SPRY) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Orbimed Capital LLC reports to the SEC
and 10 more companies
Open-market buys and sales
36 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 26, 2024 | SPRY | ↓ Sell | 83,695 | $13.00 | $1.1M | Indirect | Aug 28, 2024 (2d) |
| Aug 23, 2024 | SPRY | ↓ Sell | 868,682 | $13.24 | $11.5M | Indirect | Aug 23, 2024 (0d) |
| Aug 29, 2023 | SPRY | ↑ Buy | 500,000 | $6.20 | $3.1M | Indirect | Aug 31, 2023 (2d) |
| May 22, 2023 | PRLD | ↑ Buy | 869,565 | $5.75 | $5.0M | Indirect | May 24, 2023 (2d) |
| May 5, 2023 | KNTE | ↑ Buy | 1,377,473 | $2.80 | $3.9M | Indirect | May 8, 2023 (3d) |
| May 2, 2023 | KNTE | ↑ Buy | 1,346,342 | $2.61 | $3.5M | Indirect | May 2, 2023 (0d) |
| Jun 24, 2022 | ARQT | ↓ Sell | 341,971 | $21.31 | $7.3M | Indirect | Jun 28, 2022 (4d) |
| Apr 8, 2022 | ARQT | ↓ Sell | 878,200 | $20.68 | $18.2M | Indirect | Apr 8, 2022 (0d) |
| Mar 31, 2022 | PMVP | ↓ Sell | 474,500 | $21.63 | $10.3M | Indirect | Mar 31, 2022 (0d) |
| Feb 15, 2022 | KNTE | ↑ Buy | 195,700 | $10.17 | $2.0M | Indirect | Feb 15, 2022 (0d) |
| Sep 7, 2021 | RPTX | ↓ Sell10b5-1 | 8,084 | $33.99 | $275K | Indirect | Sep 8, 2021 (1d) |
| Sep 2, 2021 | RPTX | ↓ Sell10b5-1 | 37,864 | $34.08 | $1.3M | Indirect | Sep 2, 2021 (0d) |
| Aug 30, 2021 | RPTX | ↓ Sell10b5-1 | 18,073 | $34.07 | $616K | Indirect | Aug 30, 2021 (0d) |
| Aug 25, 2021 | RPTX | ↓ Sell10b5-1 | 18,215 | $34.17 | $622K | Indirect | Aug 25, 2021 (0d) |
| Aug 18, 2021 | RPTX | ↓ Sell10b5-1 | 20,328 | $34.10 | $693K | Indirect | Aug 19, 2021 (1d) |
| Jul 16, 2021 | IMRA | ↑ Buy | 1,666,666 | $6.00 | $10.0M | Indirect | Jul 16, 2021 (0d) |
| Feb 17, 2021 | DBTX | ↑ Buy | 1,666,666 | $18.00 | $30.0M | Indirect | Feb 19, 2021 (2d) |
| Dec 8, 2020 | SBTX | ↑ Buy | 952,377 | $21.00 | $20.0M | By OrbiMed Partners Master Fund Limited | Dec 8, 2020 (0d) |
| Dec 8, 2020 | SBTX | ↑ Buy | 238,100 | $21.00 | $5.0M | By OrbiMed Private Investments VI, LP | Dec 8, 2020 (0d) |
| Dec 2, 2020 | KNTE | ↑ Buy | 750,000 | $20.00 | $15.0M | Indirect | Dec 4, 2020 (2d) |
| Oct 2, 2020 | ARQT | ↑ Buy | 496,000 | $25.00 | $12.4M | Indirect | Oct 6, 2020 (4d) |
| Sep 25, 2020 | PRLD | ↑ Buy | 1,236,800 | $19.00 | $23.5M | Indirect | Sep 29, 2020 (4d) |
| Sep 25, 2020 | PMVP | ↑ Buy | 475,000 | $18.00 | $8.6M | Indirect | Sep 29, 2020 (4d) |
| Jun 30, 2020 | FUSN | ↑ Buy | 705,900 | $17.00 | $12.0M | By OrbiMed Private Investments VII, L.P. | Jul 2, 2020 (2d) |
| Jun 30, 2020 | FUSN | ↑ Buy | 192,100 | $17.00 | $3.3M | By OrbiMed Partners Master Fund Limited | Jul 2, 2020 (2d) |
| Jun 23, 2020 | RPTX | ↑ Buy | 774,200 | $20.00 | $15.5M | Indirect | Jun 25, 2020 (2d) |
| Mar 2, 2020 | ALEC | ↓ Sell | 1,874,203 | $26.00 | $48.7M | Indirect | Mar 4, 2020 (2d) |
| Feb 3, 2020 | ARQT | ↑ Buy | 558,888 | $17.00 | $9.5M | Indirect | Feb 4, 2020 (1d) |
| Jan 9, 2020 | ALEC | ↓ Sell | 379,997 | $19.50 | $7.4M | Indirect | Jan 13, 2020 (4d) |
| Dec 26, 2019 | ALEC | ↓ Sell | 519,385 | $19.66 | $10.2M | Indirect | Dec 26, 2019 (0d) |
| Dec 17, 2019 | ALEC | ↓ Sell | 954,100 | $18.52 | $17.7M | Indirect | Dec 19, 2019 (2d) |
| Aug 7, 2019 | ALEC | ↓ Sell | 650,000 | $17.90 | $11.6M | Indirect | Aug 9, 2019 (2d) |
| Feb 11, 2019 | ALEC | ↑ Buy | 411,700 | $19.00 | $7.8M | Indirect | Feb 11, 2019 (0d) |
| May 24, 2006 | GIVN | ↓ Sell | 22,500 | $18.14 | $408K | FN 3 and 4 | May 26, 2006 (2d) |
| May 16, 2006 | DOVP | ↓ Sell | 817,771 | $3.25 | $2.7M | Fn | May 18, 2006 (2d) |
| Aug 15, 2005 | DOVP | ↓ Sell | 223,400 | $18.33 | $4.1M | Fn | Aug 16, 2005 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other SPRY insiders
Open-market trades in the last 12 months
About Orbimed Capital LLC's insider trades
Orbimed Capital LLC is a director at ARS Pharmaceuticals (SPRY). Since Aug 15, 2005, it has reported 18 open-market purchases worth $190.0M and 18 sales worth $154.6M on SEC Form 4. There have been no open-market trades in the last 12 months.
5 sales (2% of the value sold) were made under a Rule 10b5-1 trading plan, which is set up months in advance and runs on a schedule, so they say little about how the insider sees the stock today.
Its filings also include conversions (12 filings), other transactions (3 filings), shares returned to the company (2 filings), grants and awards (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every SPRY insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.